<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20230921021053&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20230921021053&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 21 Sep 2023 06:10:56 +0000</lastbuilddate>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Acetazolamide in Acute Decompensated Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730297/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):e113. doi: 10.1016/j.jacc.2023.07.016.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730297/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730297</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.016>10.1016/j.jacc.2023.07.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730297</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Frederik H Verbrugge</dc:creator>
<dc:creator>Pieter Martens</dc:creator>
<dc:creator>Wilfried Mullens</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Acetazolamide in Acute Decompensated Heart Failure</dc:title>
<dc:identifier>pmid:37730297</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.016</dc:identifier>
</item>
<item>
<title>Acetazolamide in Acute Decompensated Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730296/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):e111. doi: 10.1016/j.jacc.2023.06.048.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730296/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730296</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.048>10.1016/j.jacc.2023.06.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730296</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Ramdas G Pai</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Acetazolamide in Acute Decompensated Heart Failure</dc:title>
<dc:identifier>pmid:37730296</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.048</dc:identifier>
</item>
<item>
<title>Impact of Socioeconomic Background on Cardiovascular Health Promotion in Early Childhood</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1377-1379. doi: 10.1016/j.jacc.2023.07.014.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730295</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.014>10.1016/j.jacc.2023.07.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730295</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Amaya de Cos-Gandoy</dc:creator>
<dc:creator>Gloria Santos-Beneit</dc:creator>
<dc:creator>Patricia Bodega</dc:creator>
<dc:creator>Jorge Baxter</dc:creator>
<dc:creator>Raquel Diaz-Munoz</dc:creator>
<dc:creator>Christopher A Hill</dc:creator>
<dc:creator>Isabel Carvajal</dc:creator>
<dc:creator>Carlos Peyra</dc:creator>
<dc:creator>Rodrigo Fernandez-Jimenez</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Socioeconomic Background on Cardiovascular Health Promotion in Early Childhood</dc:title>
<dc:identifier>pmid:37730295</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.014</dc:identifier>
</item>
<item>
<title>Ethics in Cardiovascular Care: A Call to Action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1373-1376. doi: 10.1016/j.jacc.2023.08.004.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730294</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.004>10.1016/j.jacc.2023.08.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730294</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jorge R Alegria</dc:creator>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:creator>R Scott Wright</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ethics in Cardiovascular Care: A Call to Action</dc:title>
<dc:identifier>pmid:37730294</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.004</dc:identifier>
</item>
<item>
<title>Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>A time-to-first-event composite endpoint analysis has well-known shortcomings in evaluating a treatment effect in cardiovascular clinical trials. It does not fully describe the clinical benefit of therapy because the severity of the events, events repeated over time, and clinically relevant nonsurvival outcomes cannot be considered. The generalized pairwise comparisons (GPC) method adds flexibility in defining the primary endpoint by including any number and type of outcomes that best capture...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1360-1372. doi: 10.1016/j.jacc.2023.06.047.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A time-to-first-event composite endpoint analysis has well-known shortcomings in evaluating a treatment effect in cardiovascular clinical trials. It does not fully describe the clinical benefit of therapy because the severity of the events, events repeated over time, and clinically relevant nonsurvival outcomes cannot be considered. The generalized pairwise comparisons (GPC) method adds flexibility in defining the primary endpoint by including any number and type of outcomes that best capture the clinical benefit of a therapy as compared with standard of care. Clinically important outcomes, including bleeding severity, number of interventions, and quality of life, can easily be integrated in a single analysis. The treatment effect in GPC can be expressed by the net treatment benefit, the success odds, or the win ratio. This review provides guidance on the use of GPC and the choice of treatment effect measures for the analysis and reporting of cardiovascular trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730293</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.047>10.1016/j.jacc.2023.06.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730293</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Johan Verbeeck</dc:creator>
<dc:creator>Mickaël De Backer</dc:creator>
<dc:creator>Jan Verwerft</dc:creator>
<dc:creator>Samuel Salvaggio</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Pascal Vranckx</dc:creator>
<dc:creator>Marc Buyse</dc:creator>
<dc:creator>Edgar Brunner</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37730293</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.047</dc:identifier>
</item>
<item>
<title>Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730292/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1343-1359. doi: 10.1016/j.jacc.2023.06.045.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is lacking. We assembled an international, multidisciplinary team to develop an evidence-based clinical pathway for SMuRFless CAD patients. A modified Delphi method was applied. The resulting pathway confirms underlying atherosclerosis and true SMuRFless status, ensures evidence-based secondary prevention, and considers additional tests and interventions for less typical contributors. This dedicated pathway for a previously overlooked CAD population, with an accompanying registry, aims to improve outcomes through enhanced adherence to evidence-based secondary prevention and additional diagnosis of modifiable risk factors observed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730292/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730292</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.045>10.1016/j.jacc.2023.06.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730292</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Gemma A Figtree</dc:creator>
<dc:creator>Stephen T Vernon</dc:creator>
<dc:creator>Jason A Harmer</dc:creator>
<dc:creator>Michael P Gray</dc:creator>
<dc:creator>Clare Arnott</dc:creator>
<dc:creator>Eric Bachour</dc:creator>
<dc:creator>Giannie Barsha</dc:creator>
<dc:creator>David Brieger</dc:creator>
<dc:creator>Alex Brown</dc:creator>
<dc:creator>David S Celermajer</dc:creator>
<dc:creator>Keith M Channon</dc:creator>
<dc:creator>Nicholas W S Chew</dc:creator>
<dc:creator>James J H Chong</dc:creator>
<dc:creator>Clara K Chow</dc:creator>
<dc:creator>Peter A Cistulli</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>Stuart M Grieve</dc:creator>
<dc:creator>Tomasz J Guzik</dc:creator>
<dc:creator>Emil Hagström</dc:creator>
<dc:creator>Alicia Jenkins</dc:creator>
<dc:creator>Garry Jennings</dc:creator>
<dc:creator>Anthony C Keech</dc:creator>
<dc:creator>Katharine A Kott</dc:creator>
<dc:creator>Leonard Kritharides</dc:creator>
<dc:creator>Mamas A Mamas</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Peter J Meikle</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Kazuaki Negishi</dc:creator>
<dc:creator>John O'Sullivan</dc:creator>
<dc:creator>Sanjay Patel</dc:creator>
<dc:creator>Peter J Psaltis</dc:creator>
<dc:creator>Julie Redfern</dc:creator>
<dc:creator>Philippe G Steg</dc:creator>
<dc:creator>David R Sullivan</dc:creator>
<dc:creator>Johan Sundström</dc:creator>
<dc:creator>Birgit Vogel</dc:creator>
<dc:creator>Andrew Wilson</dc:creator>
<dc:creator>Dennis Wong</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Jason C Kovacic</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>CRE for CAD Collaborators</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37730292</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.045</dc:identifier>
</item>
<item>
<title>The Burden of Chronic Medication in Congenital Heart Disease Matters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1341-1342. doi: 10.1016/j.jacc.2023.07.017.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730291</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.017>10.1016/j.jacc.2023.07.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730291</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Mary B Taylor</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Burden of Chronic Medication in Congenital Heart Disease Matters</dc:title>
<dc:identifier>pmid:37730291</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.017</dc:identifier>
</item>
<item>
<title>Chronic Medication Burden After Cardiac Surgery for Pediatric Medicaid Beneficiaries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730290/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Children who undergo cardiac surgery experience high medication burden that persists throughout childhood. Understanding chronic medication use can inform clinicians (both pediatricians and subspecialists) and policymakers, and ultimately the value of care for this medically complex population.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1331-1340. doi: 10.1016/j.jacc.2023.06.046.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Congenital heart defects are the most common and resource-intensive birth defects. As children with congenital heart defects increasingly survive beyond early childhood, it is imperative to understand longitudinal disease burden.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to examine chronic outpatient prescription medication use and expenditures for New York State pediatric Medicaid enrollees, comparing children who undergo cardiac surgery (cardiac enrollees) and the general pediatric population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a retrospective cohort study of all Medicaid enrollees age &lt;18 years using the New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources database (2006-2019). Primary outcomes were total chronic medications per person-year, enrollees per 100 person-years using ≥1 and ≥3 medications, and medication expenditures per person-year. We described and compared outcomes between cardiac enrollees and the general pediatric population. Among cardiac enrollees, multivariable regression examined associations between outcomes and clinical characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We included 5,459 unique children (32,131 person-years) who underwent cardiac surgery and 4.5 million children (22 million person-years) who did not. More than 4 in 10 children who underwent cardiac surgery used ≥1 chronic medication compared with approximately 1 in 10 children who did not have cardiac surgery. Medication expenditures were 10 times higher per person-year for cardiac compared with noncardiac enrollees. Among cardiac enrollees, disease severity was associated with chronic medication use; use was highest among infants; however, nearly one-half of adolescents used ≥1 chronic medication.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Children who undergo cardiac surgery experience high medication burden that persists throughout childhood. Understanding chronic medication use can inform clinicians (both pediatricians and subspecialists) and policymakers, and ultimately the value of care for this medically complex population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730290/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730290</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.046>10.1016/j.jacc.2023.06.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730290</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Joyce L Woo</dc:creator>
<dc:creator>Katherine A Nash</dc:creator>
<dc:creator>Kacie Dragan</dc:creator>
<dc:creator>Sarah Crook</dc:creator>
<dc:creator>Matthew Neidell</dc:creator>
<dc:creator>Stephen Cook</dc:creator>
<dc:creator>Edward L Hannan</dc:creator>
<dc:creator>Marshall Jacobs</dc:creator>
<dc:creator>Andrew B Goldstone</dc:creator>
<dc:creator>Christopher J Petit</dc:creator>
<dc:creator>Robert Vincent</dc:creator>
<dc:creator>Kathleen Walsh-Spoonhower</dc:creator>
<dc:creator>Ralph Mosca</dc:creator>
<dc:creator>T K Susheel Kumar</dc:creator>
<dc:creator>Neil Devejian</dc:creator>
<dc:creator>Steven A Kamenir</dc:creator>
<dc:creator>George M Alfieris</dc:creator>
<dc:creator>Michael F Swartz</dc:creator>
<dc:creator>David Meyer</dc:creator>
<dc:creator>Erin A Paul</dc:creator>
<dc:creator>Jane W Newburger</dc:creator>
<dc:creator>John Billings</dc:creator>
<dc:creator>Matthew M Davis</dc:creator>
<dc:creator>Brett R Anderson</dc:creator>
<dc:creator>New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources (CHS-COLOUR)</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Chronic Medication Burden After Cardiac Surgery for Pediatric Medicaid Beneficiaries</dc:title>
<dc:identifier>pmid:37730290</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.046</dc:identifier>
</item>
<item>
<title>Time to Routinely Measure eGFR and Albuminuria in Young and Middle-Aged Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1328-1330. doi: 10.1016/j.jacc.2023.07.013.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730289</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.013>10.1016/j.jacc.2023.07.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730289</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Daniel A Duprez</dc:creator>
<dc:creator>David R Jacobs</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Time to Routinely Measure eGFR and Albuminuria in Young and Middle-Aged Adults</dc:title>
<dc:identifier>pmid:37730289</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.013</dc:identifier>
</item>
<item>
<title>Impaired Renal Function and Major Cardiovascular Events in Young Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730288/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In young adults, eGFR below age-expected values were associated with an elevated risk for MACE and MACE+, warranting age-appropriate risk stratification, proactive monitoring, and timely intervention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1316-1327. doi: 10.1016/j.jacc.2023.07.012.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiovascular (CV) disease in young adults (aged 18-39 years) is on the rise. Whether subclinical reductions in kidney function (ie, estimated glomerular filtration rate [eGFR] above the current threshold for chronic kidney disease but below age-expected values) are associated with elevated CV risk is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to examine age-specific associations of subclinical eGFR reductions in young adults with major adverse cardiovascular events (MACEs) and MACE plus heart failure (MACE+).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A retrospective cohort study of 8.7 million individuals (3.6 million aged 18-39 years) was constructed using linked provincial health care data sets from Ontario, Canada (January 2008-March 2021). Cox models were used to examine the association of categorized eGFR (50-120 mL/min/1.73 m<sup>2</sup>) with MACE (first of CV mortality, acute coronary syndrome, and ischemic stroke) and MACE+, stratified according to age (18-39, 40-49, and 50-65 years).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the study cohort (mean age 41.3 years; mean eGFR 104.2 mL/min/1.73 m<sup>2</sup>; median follow-up 9.2 years), a stepwise increase in the relative risk of MACE and MACE+ was observed as early as eGFR &lt;80 mL/min/1.73 m<sup>2</sup> in young adults (eg, for MACE, at eGFR 70-79 mL/min/1.73 m<sup>2</sup>, ages 18-30 years: 2.37 events per 1,000 person years [HR: 1.31; 95% CI: 1.27-1.40]; ages 40-49 years: 6.26 events per 1,000 person years [HR: 1.09; 95% CI: 1.06-1.12]; ages 50-65 years: 14.9 events per 1,000 person years [HR: 1.07; 95% CI: 1.05-1.08]). Results persisted for each MACE component and in additional analyses (stratifying according to past CV disease, accounting for albuminuria at index, and using repeated eGFR measures).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In young adults, eGFR below age-expected values were associated with an elevated risk for MACE and MACE+, warranting age-appropriate risk stratification, proactive monitoring, and timely intervention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730288/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730288</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.012>10.1016/j.jacc.2023.07.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730288</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Junayd Hussain</dc:creator>
<dc:creator>Haris Imsirovic</dc:creator>
<dc:creator>Mark Canney</dc:creator>
<dc:creator>Edward G Clark</dc:creator>
<dc:creator>Meghan J Elliott</dc:creator>
<dc:creator>Pietro Ravani</dc:creator>
<dc:creator>Peter Tanuseputro</dc:creator>
<dc:creator>Ayub Akbari</dc:creator>
<dc:creator>Gregory L Hundemer</dc:creator>
<dc:creator>Tim Ramsay</dc:creator>
<dc:creator>Navdeep Tangri</dc:creator>
<dc:creator>Greg A Knoll</dc:creator>
<dc:creator>Manish M Sood</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impaired Renal Function and Major Cardiovascular Events in Young Adults</dc:title>
<dc:identifier>pmid:37730288</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.012</dc:identifier>
</item>
<item>
<title>Perioperative Myocardial Injury/Infarction After Cardiac Surgery: The Diagnostic Criteria Need to Change</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730287/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1313-1315. doi: 10.1016/j.jacc.2023.08.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730287/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730287</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.001>10.1016/j.jacc.2023.08.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730287</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>P J Devereaux</dc:creator>
<dc:creator>Richard Whitlock</dc:creator>
<dc:creator>Andre Lamy</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Perioperative Myocardial Injury/Infarction After Cardiac Surgery: The Diagnostic Criteria Need to Change</dc:title>
<dc:identifier>pmid:37730287</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.001</dc:identifier>
</item>
<item>
<title>Association of High-Sensitivity Cardiac Troponin T With 30-Day and 5-Year Mortality After Cardiac Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730286/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: PMI reflected by perioperative hs-cTnT release is associated with the expected 30-day mortality but not 5-year mortality. Postoperative hs-cTnT cutoffs to identify survival-relevant PMI are higher than suggested in current definitions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1301-1312. doi: 10.1016/j.jacc.2023.07.011.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The relevance of perioperative myocardial injury (PMI) after cardiac surgery for 30-day mortality and long-term survival remains to be determined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study assessed the association of PMI after cardiac surgery, reflected by postoperative troponin release, with 30-day mortality and long-term survival after: 1) coronary artery bypass grafting (CABG); 2) isolated aortic valve replacement (AVR) surgery; and 3) all other cardiac surgeries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A consecutive cohort of 8,292 patients undergoing cardiac surgery with serial perioperative high-sensitivity cardiac troponin T (hs-cTnT) measurements was retrospectively analyzed. The relationship between postoperative hs-cTnT release and 30-day mortality or 5-year mortality was analyzed after adjustment with EuroSCORE II using a Cox proportional hazards model. hs-cTnT thresholds for 30-day and 5-year mortality were determined for isolated CABG (32.3%), AVR (14%), and other cardiac surgery (53.8%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: High postoperative hs-cTnT levels were associated with higher 30-day mortality but not 5-year mortality. In CABG, median peak concentration of postoperative hs-cTnT was 1,044 ng/L, in AVR it was 502 ng/L, and in other cardiac surgery it was 1,110 ng/L. hs-cTnT thresholds defining mortality-associated PMI were as follows: for CABG, 2,385 ng/L (170× the upper reference limit of normal in a seemingly healthy population [URL]); for AVR, 568 ng/L (41× URL); and for other cardiac procedures, 1,873 ng/L (134× URL). hs-cTnT levels above the cutoffs resulted in an HR for 30-day mortality for CABG of 12.56 (P &lt; 0.001), for AVR of 4.44 (P = 0.004), and for other cardiac surgery of 3.97 (P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PMI reflected by perioperative hs-cTnT release is associated with the expected 30-day mortality but not 5-year mortality. Postoperative hs-cTnT cutoffs to identify survival-relevant PMI are higher than suggested in current definitions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730286/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730286</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.011>10.1016/j.jacc.2023.07.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730286</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Leo Pölzl</dc:creator>
<dc:creator>Clemens Engler</dc:creator>
<dc:creator>Philipp Sterzinger</dc:creator>
<dc:creator>Ronja Lohmann</dc:creator>
<dc:creator>Felix Nägele</dc:creator>
<dc:creator>Jakob Hirsch</dc:creator>
<dc:creator>Michael Graber</dc:creator>
<dc:creator>Jonas Eder</dc:creator>
<dc:creator>Sebastian Reinstadler</dc:creator>
<dc:creator>Nikolay Sappler</dc:creator>
<dc:creator>Juliane Kilo</dc:creator>
<dc:creator>Ivan Tancevski</dc:creator>
<dc:creator>Sebastian Bachmann</dc:creator>
<dc:creator>Hannes Abfalterer</dc:creator>
<dc:creator>Elfriede Ruttmann-Ulmer</dc:creator>
<dc:creator>Hanno Ulmer</dc:creator>
<dc:creator>Andrea Griesmacher</dc:creator>
<dc:creator>Samuel Heuts</dc:creator>
<dc:creator>Matthias Thielmann</dc:creator>
<dc:creator>Axel Bauer</dc:creator>
<dc:creator>Michael Grimm</dc:creator>
<dc:creator>Nikolaos Bonaros</dc:creator>
<dc:creator>Johannes Holfeld</dc:creator>
<dc:creator>Can Gollmann-Tepeköylü</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of High-Sensitivity Cardiac Troponin T With 30-Day and 5-Year Mortality After Cardiac Surgery</dc:title>
<dc:identifier>pmid:37730286</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.011</dc:identifier>
</item>
<item>
<title>Expanding Success of Mitral Transcatheter Edge-to-Edge Repair in Real-World Patients: And More Questions to Answer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730285/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1298-1300. doi: 10.1016/j.jacc.2023.08.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730285/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730285</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.002>10.1016/j.jacc.2023.08.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730285</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Mathias Orban</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Expanding Success of Mitral Transcatheter Edge-to-Edge Repair in Real-World Patients: And More Questions to Answer</dc:title>
<dc:identifier>pmid:37730285</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.002</dc:identifier>
</item>
<item>
<title>Transcatheter Edge-to-Edge Repair in 5,000 Patients With Secondary Mitral Regurgitation: COAPT Post-Approval Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37730284/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This large, contemporary, real-world study reinforces the safety and effectiveness of the MitraClip System in patients with SMR, including those who met the COAPT or MITRA-FR RCT inclusion/exclusion criteria and patients excluded from the RCTs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 26;82(13):1281-1297. doi: 10.1016/j.jacc.2023.07.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Real-world applicability of the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) randomized controlled trial (RCT) has been debated because of careful patient selection and the contrasting results of the MITRA-FR (Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients with Severe Secondary Mitral Regurgitation) RCT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The COAPT-PAS (COAPT Post-Approval Study) was initiated to assess the safety and effectiveness of the MitraClip in patients with secondary mitral regurgitation (SMR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: COAPT-PAS is a prospective, single-arm, observational study of 5,000 consecutive patients with SMR treated with the MitraClip at 406 U.S. centers participating in the TVT (Transcatheter Valve Therapy) registry from 2019 to 2020. The 1-year outcomes from the COAPT-PAS full cohort and the COAPT-like and MITRA-FR-like subgroups who met RCT inclusion/exclusion criteria are reported.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Patients in the COAPT-PAS had more comorbidities, more severe HF and functional limitations, and less guideline-directed medical therapy than those in the COAPT or MITRA-FR RCTs. Patients in the COAPT-PAS full cohort and the COAPT-like (n = 991) and MITRA-FR-like (n = 917) subgroups achieved a 97.7% MitraClip implant rate, a similar and durable reduction of mitral regurgitation to ≤2+ at 1 year (90.7%, 89.7%, and 86.6%, respectively), a large improvement in quality of life at 1 year (Kansas City Cardiomyopathy Questionnaire +29 COAPT-PAS, +27 COAPT-like, and +33 MITRA-FR-like), faster procedure times, similar or lower clinical event rates compared with the RCTs' MitraClip arms, and lower clinical event rates than the RCTs' guideline-directed medical therapy only arms. One-year heart failure hospitalizations was 18.9% in COAPT-PAS, 19.7% in COAPT-like compared with 24.9% in COAPT-RCT, and 28.7% in COAPT-PAS-MITRA-FR-like compared with 47.4% in MITRA-FR-RCT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This large, contemporary, real-world study reinforces the safety and effectiveness of the MitraClip System in patients with SMR, including those who met the COAPT or MITRA-FR RCT inclusion/exclusion criteria and patients excluded from the RCTs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37730284/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37730284</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.015>10.1016/j.jacc.2023.07.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37730284</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Kashish Goel</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Hursh Naik</dc:creator>
<dc:creator>Satya Atmakuri</dc:creator>
<dc:creator>Paul Mahoney</dc:creator>
<dc:creator>Michael A Morse</dc:creator>
<dc:creator>Vinod H Thourani</dc:creator>
<dc:creator>Pradeep Yadav</dc:creator>
<dc:creator>Wayne Batchelor</dc:creator>
<dc:creator>Jason Rogers</dc:creator>
<dc:creator>Brian Whisenant</dc:creator>
<dc:creator>Michael Rinaldi</dc:creator>
<dc:creator>James Hermiller</dc:creator>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>Colin M Barker</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transcatheter Edge-to-Edge Repair in 5,000 Patients With Secondary Mitral Regurgitation: COAPT Post-Approval Study</dc:title>
<dc:identifier>pmid:37730284</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.015</dc:identifier>
</item>
<item>
<title>Alzheimer's disease: From immunotherapy to immunoprevention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37729908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing aggregated Aβ from the brains of symptomatic patients can slow the progression of Alzheimer's disease. The clinical benefit achieved in these trials has been modest, however, highlighting the need for both a deeper understanding of disease mechanisms and the importance of intervening early in the pathogenic cascade. An immunoprevention strategy for Alzheimer's disease is required that will integrate the findings...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 17:S0092-8674(23)00910-8. doi: 10.1016/j.cell.2023.08.021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing aggregated Aβ from the brains of symptomatic patients can slow the progression of Alzheimer's disease. The clinical benefit achieved in these trials has been modest, however, highlighting the need for both a deeper understanding of disease mechanisms and the importance of intervening early in the pathogenic cascade. An immunoprevention strategy for Alzheimer's disease is required that will integrate the findings from clinical trials with mechanistic insights from preclinical disease models to select promising antibodies, optimize the timing of intervention, identify early biomarkers, and mitigate potential side effects.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37729908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37729908</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.021>10.1016/j.cell.2023.08.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37729908</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Mathias Jucker</dc:creator>
<dc:creator>Lary C Walker</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Alzheimer's disease: From immunotherapy to immunoprevention</dc:title>
<dc:identifier>pmid:37729908</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.021</dc:identifier>
</item>
<item>
<title>Stepwise emergence of the neuronal gene expression program in early animal evolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37729907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>The assembly of the neuronal and other major cell type programs occurred early in animal evolution. We can reconstruct this process by studying non-bilaterians like placozoans. These small disc-shaped animals not only have nine morphologically described cell types and no neurons but also show coordinated behaviors triggered by peptide-secreting cells. We investigated possible neuronal affinities of these peptidergic cells using phylogenetics, chromatin profiling, and comparative single-cell...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14:S0092-8674(23)00917-0. doi: 10.1016/j.cell.2023.08.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The assembly of the neuronal and other major cell type programs occurred early in animal evolution. We can reconstruct this process by studying non-bilaterians like placozoans. These small disc-shaped animals not only have nine morphologically described cell types and no neurons but also show coordinated behaviors triggered by peptide-secreting cells. We investigated possible neuronal affinities of these peptidergic cells using phylogenetics, chromatin profiling, and comparative single-cell genomics in four placozoans. We found conserved cell type expression programs across placozoans, including populations of transdifferentiating and cycling cells, suggestive of active cell type homeostasis. We also uncovered fourteen peptidergic cell types expressing neuronal-associated components like the pre-synaptic scaffold that derive from progenitor cells with neurogenesis signatures. In contrast, earlier-branching animals like sponges and ctenophores lacked this conserved expression. Our findings indicate that key neuronal developmental and effector gene modules evolved before the advent of cnidarian/bilaterian neurons in the context of paracrine cell signaling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37729907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37729907</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.027>10.1016/j.cell.2023.08.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37729907</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Sebastián R Najle</dc:creator>
<dc:creator>Xavier Grau-Bové</dc:creator>
<dc:creator>Anamaria Elek</dc:creator>
<dc:creator>Cristina Navarrete</dc:creator>
<dc:creator>Damiano Cianferoni</dc:creator>
<dc:creator>Cristina Chiva</dc:creator>
<dc:creator>Didac Cañas-Armenteros</dc:creator>
<dc:creator>Arrate Mallabiabarrena</dc:creator>
<dc:creator>Kai Kamm</dc:creator>
<dc:creator>Eduard Sabidó</dc:creator>
<dc:creator>Harald Gruber-Vodicka</dc:creator>
<dc:creator>Bernd Schierwater</dc:creator>
<dc:creator>Luis Serrano</dc:creator>
<dc:creator>Arnau Sebé-Pedrós</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Stepwise emergence of the neuronal gene expression program in early animal evolution</dc:title>
<dc:identifier>pmid:37729907</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.027</dc:identifier>
</item>
<item>
<title>Deep Learning for Cardiovascular Imaging: A Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37728933/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Deep learning has the potential to meaningfully affect the field of CVI. Rather than a threat, DL could be seen as a partner to cardiovascular imagers in reducing technical burden and improving efficiency and quality of care. High-quality prospective evidence is still needed to demonstrate how the benefits of DL CVI systems may outweigh the risks.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 20. doi: 10.1001/jamacardio.2023.3142. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Artificial intelligence (AI), driven by advances in deep learning (DL), has the potential to reshape the field of cardiovascular imaging (CVI). While DL for CVI is still in its infancy, research is accelerating to aid in the acquisition, processing, and/or interpretation of CVI across various modalities, with several commercial products already in clinical use. It is imperative that cardiovascular imagers are familiar with DL systems, including a basic understanding of how they work, their relative strengths compared with other automated systems, and possible pitfalls in their implementation. The goal of this article is to review the methodology and application of DL to CVI in a simple, digestible fashion toward demystifying this emerging technology.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBSERVATIONS: At its core, DL is simply the application of a series of tunable mathematical operations that translate input data into a desired output. Based on artificial neural networks that are inspired by the human nervous system, there are several types of DL architectures suited to different tasks; convolutional neural networks are particularly adept at extracting valuable information from CVI data. We survey some of the notable applications of DL to tasks across the spectrum of CVI modalities. We also discuss challenges in the development and implementation of DL systems, including avoiding overfitting, preventing systematic bias, improving explainability, and fostering a human-machine partnership. Finally, we conclude with a vision of the future of DL for CVI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Deep learning has the potential to meaningfully affect the field of CVI. Rather than a threat, DL could be seen as a partner to cardiovascular imagers in reducing technical burden and improving efficiency and quality of care. High-quality prospective evidence is still needed to demonstrate how the benefits of DL CVI systems may outweigh the risks.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37728933/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37728933</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3142>10.1001/jamacardio.2023.3142</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37728933</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Ramsey M Wehbe</dc:creator>
<dc:creator>Aggelos K Katsaggleos</dc:creator>
<dc:creator>Kristian J Hammond</dc:creator>
<dc:creator>Ha Hong</dc:creator>
<dc:creator>Faraz S Ahmad</dc:creator>
<dc:creator>David Ouyang</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Patrick M McCarthy</dc:creator>
<dc:creator>James D Thomas</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Deep Learning for Cardiovascular Imaging: A Review</dc:title>
<dc:identifier>pmid:37728933</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3142</dc:identifier>
</item>
<item>
<title>Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37728907/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In this study, mirabegron therapy had a neutral effect on LV mass or diastolic function over 12 months among patients who had structural heart disease with no or mild HF symptoms.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 20. doi: 10.1001/jamacardio.2023.3003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β3-adrenergic receptors (β3ARs) may represent a new target, as their activation attenuates LV remodeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine whether activation of β3ARs by repurposing a β3AR agonist, mirabegron, is safe and effective in preventing progression of LV hypertrophy and diastolic dysfunction among patients with pre- or mild HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The Beta3-LVH prospective, triple-blind, placebo-controlled phase 2b randomized clinical trial enrolled patients between September 12, 2016, and February 26, 2021, with a follow-up of 12 months. The trial was conducted at 10 academic hospitals in 8 countries across Europe (Germany, Poland, France, Belgium, Italy, Portugal, Greece, and the UK). Patients aged 18 years or older with or without HF symptoms (maximum New York Heart Association class II) were screened for the presence of LV hypertrophy (increased LV mass index [LVMI] of ≥95 g/m2 for women or ≥115 g/m2 for men) or maximum wall thickness of 13 mm or greater using echocardiography. Data analysis was performed in August 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Participants were randomly assigned (1:1) to mirabegron (50 mg/d) or placebo, stratified by the presence of atrial fibrillation and/or type 2 diabetes, for 12 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end points were LVMI determined using cardiac magnetic resonance imaging and LV diastolic function (early diastolic tissue Doppler velocity [E/e'] ratio assessed using Doppler echocardiography) at 12 months. Patients with at least 1 valid measurement of either primary end point were included in the primary analysis. Safety was assessed for all patients who received at least 1 dose of study medication.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 380 patients screened, 296 were enrolled in the trial. There were 147 patients randomized to mirabegron (116 men [79%]; mean [SD] age, 64.0 [10.2] years) and 149 to placebo (112 men [75%]; mean [SD] age, 62.2 [10.9] years). All patients were included in the primary intention-to-treat analysis. At 12 months, the baseline and covariate-adjusted differences between groups included a 1.3-g/m2 increase in LVMI (95% CI, -0.15 to 2.74; P = .08) and a -0.15 decrease in E/e' (95% CI, -0.69 to 0.4; P = .60). A total of 213 adverse events (AEs) occurred in 82 mirabegron-treated patients (including 31 serious AEs in 19 patients) and 215 AEs occurred in 88 placebo-treated patients (including 30 serious AEs in 22 patients). No deaths occurred during the trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this study, mirabegron therapy had a neutral effect on LV mass or diastolic function over 12 months among patients who had structural heart disease with no or mild HF symptoms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02599480.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37728907/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37728907</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3003>10.1001/jamacardio.2023.3003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37728907</guid>
<pubDate>Wed, 20 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jean-Luc Balligand</dc:creator>
<dc:creator>Dulce Brito</dc:creator>
<dc:creator>Oana Brosteanu</dc:creator>
<dc:creator>Barbara Casadei</dc:creator>
<dc:creator>Christophe Depoix</dc:creator>
<dc:creator>Frank Edelmann</dc:creator>
<dc:creator>Vanessa Ferreira</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Bernhard Gerber</dc:creator>
<dc:creator>Damien Gruson</dc:creator>
<dc:creator>Dirk Hasenclever</dc:creator>
<dc:creator>Kristian Hellenkamp</dc:creator>
<dc:creator>Ignatios Ikonomidis</dc:creator>
<dc:creator>Bartosz Krakowiak</dc:creator>
<dc:creator>Renaud Lhommel</dc:creator>
<dc:creator>Masliza Mahmod</dc:creator>
<dc:creator>Stefan Neubauer</dc:creator>
<dc:creator>Alexandre Persu</dc:creator>
<dc:creator>Stefan Piechnik</dc:creator>
<dc:creator>Burkert Pieske</dc:creator>
<dc:creator>Elisabeth Pieske-Kraigher</dc:creator>
<dc:creator>Fausto Pinto</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Jean-Noël Trochu</dc:creator>
<dc:creator>Nancy Van Overstraeten</dc:creator>
<dc:creator>Rolf Wachter</dc:creator>
<dc:creator>Anne-Catherine Pouleur</dc:creator>
<dc:date>2023-09-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37728907</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3003</dc:identifier>
</item>
<item>
<title>CD1 lipidomes reveal lipid-binding motifs and size-based antigen-display mechanisms</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37725977/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>The CD1 system binds lipid antigens for display to T cells. Here, we solved lipidomes for the four human CD1 antigen-presenting molecules, providing a map of self-lipid display. Answering a basic question, the detection of >;2,000 CD1-lipid complexes demonstrates broad presentation of self-sphingolipids and phospholipids. Whereas peptide antigens are chemically processed, many lipids are presented in an unaltered form. However, each type of CD1 protein differentially edits the self-lipidome to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 12:S0092-8674(23)00912-1. doi: 10.1016/j.cell.2023.08.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The CD1 system binds lipid antigens for display to T cells. Here, we solved lipidomes for the four human CD1 antigen-presenting molecules, providing a map of self-lipid display. Answering a basic question, the detection of >;2,000 CD1-lipid complexes demonstrates broad presentation of self-sphingolipids and phospholipids. Whereas peptide antigens are chemically processed, many lipids are presented in an unaltered form. However, each type of CD1 protein differentially edits the self-lipidome to show distinct capture motifs based on lipid length and chemical composition, suggesting general antigen display mechanisms. For CD1a and CD1d, lipid size matches the CD1 cleft volume. CD1c cleft size is more variable, and CD1b is the outlier, where ligands and clefts show an extreme size mismatch that is explained by uniformly seating two small lipids in one cleft. Furthermore, the list of compounds that comprise the integrated CD1 lipidome supports the ongoing discovery of lipid blockers and antigens for T cells.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37725977/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37725977</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.022>10.1016/j.cell.2023.08.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37725977</guid>
<pubDate>Tue, 19 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Shouxiong Huang</dc:creator>
<dc:creator>Adam Shahine</dc:creator>
<dc:creator>Tan-Yun Cheng</dc:creator>
<dc:creator>Yi-Ling Chen</dc:creator>
<dc:creator>Soo Weei Ng</dc:creator>
<dc:creator>Gautham R Balaji</dc:creator>
<dc:creator>Rachel Farquhar</dc:creator>
<dc:creator>Stephanie Gras</dc:creator>
<dc:creator>Clare S Hardman</dc:creator>
<dc:creator>John D Altman</dc:creator>
<dc:creator>Nabil Tahiri</dc:creator>
<dc:creator>Adriaan J Minnaard</dc:creator>
<dc:creator>Graham S Ogg</dc:creator>
<dc:creator>Jacob A Mayfield</dc:creator>
<dc:creator>Jamie Rossjohn</dc:creator>
<dc:creator>D Branch Moody</dc:creator>
<dc:date>2023-09-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>CD1 lipidomes reveal lipid-binding motifs and size-based antigen-display mechanisms</dc:title>
<dc:identifier>pmid:37725977</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.022</dc:identifier>
</item>
<item>
<title>Life-threatening left atrioesophageal fistula complicated with catheter ablation for atrial fibrillation in a patient with aortic stent graft</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37725918/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 19:ehad609. doi: 10.1093/eurheartj/ehad609. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37725918/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37725918</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad609>10.1093/eurheartj/ehad609</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37725918</guid>
<pubDate>Tue, 19 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Yuya Tanaka</dc:creator>
<dc:creator>Kenji Kuroki</dc:creator>
<dc:creator>Shigeaki Kaga</dc:creator>
<dc:date>2023-09-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Life-threatening left atrioesophageal fistula complicated with catheter ablation for atrial fibrillation in a patient with aortic stent graft</dc:title>
<dc:identifier>pmid:37725918</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad609</dc:identifier>
</item>
<item>
<title>Lack of association between fluoroquinolone and aortic aneurysm or dissection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37724037/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230921021053&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: There was no significant difference in the risk of AA/AD in patients who were administered oral FQ compared to those administered 3GC. The study findings suggest that the use of FQ should not be deterred when clinically indicated.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 19:ehad627. doi: 10.1093/eurheartj/ehad627. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: An increased risk of aortic aneurysm and aortic dissection (AA/AD) has been reported with fluoroquinolone (FQ) use. However, recent studies suggested confounding factors by indication. This study aimed to investigate the risk of AA/AD associated with FQ use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This nationwide population-based study included adults aged ≥20 years who received a prescription of oral FQ or third-generation cephalosporins (3GC) during outpatient visits from 2005 to 2016. Data source was the National Health Insurance Service reimbursement database. The primary outcome was hospitalization or in-hospital death with a primary diagnosis of AA/AD. A self-controlled case series (SCCS) and Cox proportional hazards model were used. Self-controlled case series compared the incidence of the primary outcome in the risk period vs. the control periods.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 954 308 patients (777 109 with FQ and 177 199 with 3GC use) were included. The incidence rate ratios for AA/AD between the risk period and the pre-risk period were higher in the 3GC group [11.000; 95% confidence interval (CI) 1.420-85.200] compared to the FQ group (2.000; 95% CI 0.970-4.124). The overall incidence of AA/AD among the patients who received FQ and 3GC was 5.40 and 8.47 per 100 000 person-years. There was no significant difference in the risk between the two groups (adjusted hazard ratio 0.752; 95% CI 0.515-1.100) in the inverse probability of treatment-weighted Cox proportional hazards model. Subgroup and sensitivity analysis showed consistent results.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: There was no significant difference in the risk of AA/AD in patients who were administered oral FQ compared to those administered 3GC. The study findings suggest that the use of FQ should not be deterred when clinically indicated.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37724037/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230921021053&v=2.17.9.post6+86293ac">37724037</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad627>10.1093/eurheartj/ehad627</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37724037</guid>
<pubDate>Tue, 19 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Kyungmin Huh</dc:creator>
<dc:creator>Minsun Kang</dc:creator>
<dc:creator>Jaehun Jung</dc:creator>
<dc:date>2023-09-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Lack of association between fluoroquinolone and aortic aneurysm or dissection</dc:title>
<dc:identifier>pmid:37724037</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad627</dc:identifier>
</item>





























</channel>
</rss>